Advertisement
Screener

CORCEPT THERAPEUTICS INC (CORT) Overview

CORCEPT THERAPEUTICS INC (CORT) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.36; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.30; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.16; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.29; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$30.54$40.79$54.47$72.75$97.15$129.752025-09-292026-09-29$15.70$23.96$36.55$55.75$85.05$129.752021-09-292026-09-29$5.95$11.02$20.41$37.81$70.04$129.752016-09-292026-09-29$0.66$1.91$5.48$15.74$45.19$129.752006-09-292026-09-29$0.66$1.91$5.48$15.74$45.19$129.752004-04-142026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$114.74
Previous close
$115.63
Change
-$0.89
Change (%)
-0.77%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

CORT
+229.49%
S&P 500
(m)

1 year

CORT
+36.67%
S&P 500
(m)

3 years

CORT
+320.78%
S&P 500
(m)

5 years

CORT
+475.33%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.36

-0.38-0.150.080.310.5431 Mar 2025: estimate (m); actual 0.1731 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.2930 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.1630 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.3031 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.3630 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.36(m)(m)
1 Jan 202631 Mar 2026(m)-0.30(m)(m)
1 Jul 202530 Sept 2025(m)0.16(m)(m)
1 Apr 202530 Jun 2025(m)0.29(m)(m)
1 Jan 202531 Mar 2025(m)0.17(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 0.82

0.740.911.071.241.4131 Dec 2021: estimate (m); actual 0.8931 Dec 2021(m)31 Dec 2022: estimate (m); actual 0.8731 Dec 2022(m)31 Dec 2023: estimate (m); actual 0.9431 Dec 2023(m)31 Dec 2024: estimate (m); actual 1.2331 Dec 2024(m)31 Dec 2025: estimate (m); actual 0.8231 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)0.82(m)(m)
1 Jan 202431 Dec 2024(m)1.23(m)(m)
1 Jan 202331 Dec 2023(m)0.94(m)(m)
1 Jan 202231 Dec 2022(m)0.87(m)(m)
1 Jan 202131 Dec 2021(m)0.89(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 256.15M ■ Earnings 42.99M — Profit margin 16.78%

-66.31M-20.3%52.69M-7.6%171.69M5.1%290.70M17.8%30 Sept 2025: revenue 207.64M; earnings 19.67M; profit margin 9.47%30 Sept 202531 Dec 2025: revenue 202.13M*; earnings 24.29M*; profit margin 12.02%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 164.90M; earnings -31.76M; profit margin -19.26%31 Mar 202630 Jun 2026: revenue 256.15M; earnings 42.99M; profit margin 16.78%30 Jun 2026

31 Dec 2025 ■ Revenue 761.41M ■ Earnings 99.65M — Profit margin 13.09%

-91.37M12.1%223.35M16.8%538.06M21.5%852.78M26.2%31 Dec 2022: revenue 401.86M; earnings 101.42M; profit margin 25.24%31 Dec 202231 Dec 2023: revenue 482.38M; earnings 106.14M; profit margin 22.00%31 Dec 202331 Dec 2024: revenue 675.04M; earnings 141.21M; profit margin 20.92%31 Dec 202431 Dec 2025: revenue 761.41M; earnings 99.65M; profit margin 13.09%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$114.74(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$114.74High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning CORT

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$55.18M
Profit margin
6.64%
Return on assets · 12 month
6.53%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
730.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.76M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-2.44%*
Total return · month
0.80%*
Total return · quarter
30.46%*
Total return · half year
204.95%*
Total return · year to date
229.49%*
Total return · 1 year
36.67%*
Total return · 3 years
320.78%*
Total return · 5 years
475.33%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$830.81M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

CORCEPT THERAPEUTICS INC Overview

View more →

(m)

(m)

SEC CIK
1088856
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY, California, 94065, United States
Fiscal year end
1231
Phone
650.688.8803

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52